110 related articles for article (PubMed ID: 30953753)
1. The EU regulatory landscape of non-biological complex drugs (NBCDs) follow-on products: Observations and recommendations.
Klein K; Stolk P; De Bruin ML; Leufkens HGM; Crommelin DJA; De Vlieger JSB
Eur J Pharm Sci; 2019 May; 133():228-235. PubMed ID: 30953753
[TBL] [Abstract][Full Text] [Related]
2. Factors associated with hematological adverse reactions of drugs authorized via the centralized procedure.
Stević I; Janković SM; Georgiev AM; Marinković V; Lakić D
Sci Rep; 2024 Apr; 14(1):9074. PubMed ID: 38643204
[TBL] [Abstract][Full Text] [Related]
3. Regulatory Framework for Drug-Device Combination Products in the United States, Europe, and Korea.
Kim JH; Kwon S; Seol JE; Kim MH; Kim SD
Ther Innov Regul Sci; 2024 May; ():. PubMed ID: 38717522
[TBL] [Abstract][Full Text] [Related]
4. EMA commentary on the guideline on quality, nonclinical and clinical aspects of medicinal products containing genetically modified cells.
Celis P; Farinelli G; Hidalgo-Simon A; Meij P; Tihaya M; Schüssler-Lenz M; Timón M
Br J Clin Pharmacol; 2024 May; 90(5):1203-1212. PubMed ID: 38565322
[TBL] [Abstract][Full Text] [Related]
5. Tackling the challenges of nanomedicines: are we ready?
Hertig JB; Shah VP; Flühmann B; Mühlebach S; Stemer G; Surugue J; Moss R; Di Francesco T
Am J Health Syst Pharm; 2021 Jun; 78(12):1047-1056. PubMed ID: 33599767
[TBL] [Abstract][Full Text] [Related]
6. Where is European Regulation 536/2014 Taking Us?
Fox AW
Pharmaceut Med; 2023 Sep; 37(5):343-347. PubMed ID: 37353716
[TBL] [Abstract][Full Text] [Related]
7. Live Biotherapeutic Products, A Road Map for Safety Assessment.
Rouanet A; Bolca S; Bru A; Claes I; Cvejic H; Girgis H; Harper A; Lavergne SN; Mathys S; Pane M; Pot B; Shortt C; Alkema W; Bezulowsky C; Blanquet-Diot S; Chassard C; Claus SP; Hadida B; Hemmingsen C; Jeune C; Lindman B; Midzi G; Mogna L; Movitz C; Nasir N; Oberreither M; Seegers JFML; Sterkman L; Valo A; Vieville F; Cordaillat-Simmons M
Front Med (Lausanne); 2020; 7():237. PubMed ID: 32637416
[TBL] [Abstract][Full Text] [Related]
8. Development of Cell and Gene Therapies for Clinical Use in the US and EU: Summary of Regulatory Guidelines.
Rotte A
Curr Gene Ther; 2024 Apr; ():. PubMed ID: 38676481
[TBL] [Abstract][Full Text] [Related]
9. Non-biological Complex Drugs (NBCDs): Complex Pharmaceuticals in Need of Individual Robust Clinical Assessment Before Any Therapeutic Equivalence Decision.
Gaspar RS; Silva-Lima B; Magro F; Alcobia A; da Costa FL; Feio J
Front Med (Lausanne); 2020; 7():590527. PubMed ID: 33330550
[TBL] [Abstract][Full Text] [Related]
10. Synthetic polypeptides using a biologic as a reference medicinal product - the European landscape of regulatory approvals.
Klein K; Heisterberg J; Stolk P
Front Med (Lausanne); 2024; 11():1335928. PubMed ID: 38681047
[TBL] [Abstract][Full Text] [Related]
11. Exploiting Pharma 4.0 Technologies in the Non-Biological Complex Drugs Manufacturing: Innovations and Implications.
Malheiro V; Duarte J; Veiga F; Mascarenhas-Melo F
Pharmaceutics; 2023 Oct; 15(11):. PubMed ID: 38004525
[TBL] [Abstract][Full Text] [Related]
12. Differences in Physico-Chemical Properties and Immunological Response in Nanosimilar Complex Drugs: The Case of Liposomal Doxorubicin.
Lipsa D; Magrì D; Della Camera G; La Spina R; Cella C; Garmendia-Aguirre I; Mehn D; Ruiz-Moreno A; Fumagalli F; Calzolai L; Gioria S
Int J Mol Sci; 2023 Sep; 24(17):. PubMed ID: 37686418
[TBL] [Abstract][Full Text] [Related]
13. Regulatory considerations for generic products of non-biological complex drugs.
Liu YH; Chen YS; Tseng T; Jiang ML; Gau CS; Chang LC
J Food Drug Anal; 2023 Mar; 31(1):20-31. PubMed ID: 37224550
[TBL] [Abstract][Full Text] [Related]
14. Regulatory assessment of nano-enabled health products in public health interest. Position of the scientific advisory board of the French National Agency for the Safety of Medicines and Health Products.
Oualikene-Gonin W; Sautou V; Ezan E; Bastos H; Bellissant E; Belgodère L; Maison P; Ankri J;
Front Public Health; 2023; 11():1125577. PubMed ID: 36935690
[TBL] [Abstract][Full Text] [Related]
15. Analysis of complex drugs by comprehensive two-dimensional gas chromatography and high-resolution mass spectrometry: detailed chemical description of the active pharmaceutical ingredient sodium bituminosulfonate and its process intermediates.
Schwalb L; Tiemann O; Käfer U; Gröger T; Rüger CP; Gayko G; Zimmermann R
Anal Bioanal Chem; 2023 May; 415(13):2471-2481. PubMed ID: 36401638
[TBL] [Abstract][Full Text] [Related]
16. Future perspectives for advancing regulatory science of nanotechnology-enabled health products.
Halamoda-Kenzaoui B; Geertsma R; Pouw J; Prina-Mello A; Carrer M; Roesslein M; Sips A; Weltring KM; Spring K; Bremer-Hoffmann S
Drug Deliv Transl Res; 2022 Sep; 12(9):2145-2156. PubMed ID: 35691982
[TBL] [Abstract][Full Text] [Related]
17. Nanomedicines and Nanosimilars-Why a Robust Centralised Regulatory Framework Is Essential to Enhance Patient Safety.
Isles MP
Front Pharmacol; 2021; 12():787239. PubMed ID: 35280250
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
